Meininger, Cynthia individual record

My research focuses primarily on the vascular complications of diabetes. Using animal models of human diabetes, we have demonstrated that an inability of endothelial cells to produce nitric oxide may be partly responsible for these vascular complications. We are developing a gene/drug therapy approach for treating cardiovascular disease associated with diabetes. Targeted nanoparticles will deliver either the gene for GTPCH or BH4 itself into endothelial cells oxidatively damaged by diabetes to correct endothelial GTPCH deficiency, increase tetrahydrobiopterin levels, restore nitric oxide production and reverse the vascular dysfunction seen in diabetes. Our endothelium-targeting nanoparticle approach will not only reverse the damage caused by disease but will increase antioxidant levels to protect the endothelial cells from future damage and/or dysfunction.

selected publications
Academic Articles116
  • Flynn, N. E., Meininger, C. J., Haynes, T. E., Shi, W., & Wu, G. (2005). Mechanisms for dietary regulation of nitric oxide synthesis in mammals. Nutrients and Cell Signaling. (pp. 225-252).
  • Meininger, C. J., & Wu, G. (2002). [24] Regulation of endothelial cell proliferation by nitric oxide. MACROMOLECULAR CRYSTALLOGRAPHY, PT D. Redox Cell Biology and Genetics Part A. (pp. 280-295). Elsevier.
    doi badge pubmed badge
Conference Papers14
First Name
Last Name
mailing address
Texas A&M Health Science Center; Medical Physiology; 1114 TAMUS
Temple, TX 76504